IMPRESS-Norway has been open for inclusion for 3.5 years and so far, more than 2100 patients have had their tumour sequenced through InPreD and more than 430 patients have been offered a new treatment option through this trial. Early results published in Acta Oncologica 1 in May 2024, including data from 186 patients undergoing treatment, …
The Regional Health Authorities in Norway has recently decided to reimburse patients who are included in the first expansion cohort in IMPRESS-Norway according to the pay-for-performance model described below. IMPRESS-Norway is a precision medicine trial that tests approved drugs on new indications based on genetic changes in the patient’s tumor. The study started in April last year, and so far …
Incyte Inc. has several relevant cancer drugs in its portfolio. Initially, Incyte will support IMPRESS with its drug Pemazyre. Pemazyre is a targeted drug that attacks fibroblast growth factor receptor 2 (FGFR2). The drug is currently approved for use in adults with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. FGFR2 fusions / …
IMPRESS-Norway started inclusion of patients 1. April 2021 and at the end of January 2022 50 patients have been offered treatment in a IMPRESS-Norway cohort and over 170 patients have been analyzed in National Molecular Tumor Board meetings.